stella
beta
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors — Stella
Home
/
HRD Cancer
/
View on ClinicalTrials.gov
Recruiting
Back to HRD Cancer trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
United States
National Institutes of Health Clinical Center, Bethesda, Maryland